Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRT811

Small molecule · Inhibitor of PRMT5 · developed by Prelude Therapeutics

Phase 1 Most advanced trial (none active)
PRLD Developer
1 Registered trials

What is PRT811?

PRT811 is an orally available small molecule that selectively binds and inhibits PRMT5, a type II methyltransferase that forms monomethylarginine and symmetric dimethylarginine on histones and other proteins. Inhibition reduces methylated arginine on histones H2A, H3 and H4, altering expression of genes that govern cellular proliferation. It is being studied in advanced solid tumors and recurrent glioma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
PRMT5
Mechanism
Inhibitor of PRMT5
Pathways
histone arginine methylation, gene expression regulation of proliferation genes
Therapy area
Oncology
Developer
Prelude Therapeutics Incorporated (PRLD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04089449 Phase 1 Advanced Solid Tumor Completed PRLD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorRecurrent Glioma

Other drugs acting on PRMT5

More from Prelude Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PRLD page.

Follow PRLD, the company behind PRT811

See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRLD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.